Skip to content

    Hepatitis Health Center

    Font Size
    A
    A
    A

    FDA Approves Long-Acting Treatment for Hepatitis C


    WebMD Health News

    Jan. 22, 2001 (Washington) -- Federal health regulators on Monday approved the first long-acting treatment for the liver infection hepatitis C, offering at least some patients the option of an easier treatment regimen.

    This means that patients with persistent, or chronic, infection can now have a once-weekly injection, instead of three times a week, at twice the effectiveness. And although there is still one other regimen out there that is considered the best option for many people, this new treatment has its advantages.

    The most frightening thing about hepatitis C is its tendency to cause chronic liver disease. At least 75% of patients with acute hepatitis C ultimately develop a chronic infection, and most of these patients have accompanying persistent liver disease. Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer.

    Two different regimens previously have been approved as therapy for hepatitis C in the U.S. -- therapy with interferon-alpha alone, which has anticancer properties, and also is effective in fighting viral infections, or combination therapy with interferon-alpha and ribavirin, which also is effective at treating some viral infections

    The newly approved drug, Peg-Intron, is a once-a-week version of interferon-alpha.

    But studies have indicated that the best therapy currently available for hepatitis C infection is the combination therapy.

    The safety and effectiveness of Peg-Intron was demonstrated in a clinical trial involving about 1,200 adult patients, in which 24% of the study population responded to Peg-Intron treatment, compared to 12% of those patients on the interferon-alpha alone.

    However, in a second trial involving about 1,700 patients, the combination therapy still proved best. Approximately 40% of the study population responded to the interferon-alpha and ribavirin vs. about 15% of those patients on interferon-alpha alone.

    This FDA approval does not include approval of Peg-Intron for use in combination with ribavirin.

    Still, the approval of Peg-Intron represents an important development, says Richard W. Zahn, president of Schering Laboratories, the maker of both Rebetron (the combination drug) and Peg-Intron.

    Zahn explains that because patients can take the drug weekly, they may take it more readily and stick to treatment.

    Today on WebMD

    Hepatitus C virus
    Types, symptoms and treatments.
    liver illustration
    Myths and facts about this essential organ.
     
    woman eating apple
    What you need to know.
    doctor and patient
    What causes it?
     
    Hepatitis C Treatment
    Article
    Syringes and graph illustration
    Tool
     
    liver illustration
    Quiz
    passport, pills and vaccine
    Slideshow
     
    Scientist looking in microscope
    Slideshow
    Fatty Liver Disease
    Article
     
    Digestive Diseases Liver Transplantation
    Article
    Picture Of The Liver
    Image Collection